Table 1.
Preclinical studies of CAR-NK cell therapy.
| Malignancy | Target | Source of NK cells | Reference |
|---|---|---|---|
| Hematological cancer | |||
| B-cell malignancies | CD19 | NK-92, PB-NK or CB-NK | (40, 57–60) |
| CD20 | NK-92 | (61) | |
| Flt3 | NK-92 | (62) | |
| Multiple myeloma | CD138 | NK-92 | (65) |
| BCMA | NK-92 | (66) | |
| CS1 | NK-92 | (67) | |
| NKG2D | PB-NK | (77) | |
| T-cell malignancies | CD3 | NK-92 | (68) |
| CD5 | NK-92 | (69) | |
| CD7 | NK-92 | (70) | |
| AML | NKG2D | PB-NK | (77) |
| Solid cancer | |||
| Glioblastoma | HER2 | NK-92 | (79) |
| EGFR and/or EGFRvIII | NK-92, NKL, KHYG1 or YTS | (80–84) | |
| Breast cancer | HER2 | NK-92 | (29, 85, 86) |
| EGFR and/or EGFRvIII | NK-92 or PB-NK | (87) | |
| EpCAM | NK-92 | (88) | |
| TF | NK-92 | (89) | |
| B7-H6 | NK-92 | (90) | |
| Ovarian cancer | HLA-G | PB-NK | (91) |
| CD24 | NK-92 | (92) | |
| CD44 | NK-92 | (93) | |
| CD133 | NK-92 | (94) | |
| Mesothelin | iPSC-NK or NK-92 | (95, 96) | |
| αFR | NK-92 | (97) | |